Author Correction: Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer

Affiliations

• ¹ Ovarian Cancer Research Center, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
• ² Department of Oncology, Lausanne University Hospital (CHUV), Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland. Lai-Lai-Cheryl.Chiang@chuv.ch.
• ³ Department of Oncology, Lausanne University Hospital (CHUV), Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.
• ⁴ Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
• ⁵ Institute of Animal Pathology, COMPATH, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
• ⁶ School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
• ⁷ Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
• ⁸ Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
• ⁹ Department of Oncology, Lausanne University Hospital (CHUV), Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland. Lana.Kandalaft@chuv.ch.
• ¹⁰ Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland. Lana.Kandalaft@chuv.ch.